- Conditions
- Sjögren's Syndrome
- Interventions
- Dazodalibep
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 844 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 31
- States / cities
- Avondale, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 27 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 652
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Dry Eye
- Interventions
- Lubricant Eye Drops FID 112903, Optive Lubricant Eye Drops
- Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Mansfield, Texas
- Conditions
- Dry Eye Syndromes
- Interventions
- Cyclosporine, Refresh Plus
- Drug
- Lead sponsor
- Innovative Medical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Greensboro, North Carolina
- Conditions
- Dry Eye Disease
- Interventions
- 0.02% Betamethasone Sodium Phosphate, 0.04% Betamethasone Sodium Phosphate, Placebo
- Drug
- Lead sponsor
- Surface Ophthalmics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 139 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 28
- States / cities
- Dothan, Alabama • Azusa, California • Mission Hills, California + 25 more
- Conditions
- Leukodystrophy, White Matter Disease, Leukoencephalopathies, 4H Syndrome, Adrenoleukodystrophy, AMN, ALD, ALD Gene Mutation, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, Adrenomyeloneuropathy, Aicardi Goutieres Syndrome, AGS, Alexander Disease, Alexanders Leukodystrophy, AxD, ADLD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, Krabbe Disease, GALC Deficiency, Globoid Leukodystrophy, TUBB4A-Related Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, Megalencephalic Leukoencephalopathy With Subcortical Cysts, MLD, Metachromatic Leukodystrophy, PMD, Pelizaeus-Merzbacher Disease, PLP1 Null Syndrome, PLP1 Gene Duplication | Blood or Tissue | Mutations, Pelizaeus Merzbacher Like Disease, Peroxisomal Biogenesis Disorder, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Vanishing White Matter Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, Cockayne Syndrome, Multiple Sulfatase Deficiency, Gangliosidoses, GM2 Gangliosidosis, BPAN, Labrune Syndrome, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
- Interventions
- Not listed
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- Not listed
- Enrollment
- 12,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2030
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Orange, California • Palo Alto, California + 18 more
- Conditions
- Dry Eye, Sjogren's Syndrome
- Interventions
- Not listed
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Healthy, Sicca Syndrome, Sjögren's Syndrome
- Interventions
- Biopsy
- Procedure
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 4
- States / cities
- Hartford, Connecticut • Boston, Massachusetts • Philadelphia, Pennsylvania + 1 more
- Conditions
- Dry Eye Syndromes
- Interventions
- Dextenza 0.4Mg Intracanalicular Insert, Over the counter Artificial tears
- Drug · Other
- Lead sponsor
- The Eye Centers of Racine and Kenosha
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Racine, Wisconsin
- Conditions
- Dry Eye Disease (DED)
- Interventions
- NOV03, Placebo
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 599 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Glendale, California + 25 more
- Conditions
- Sjogren's Syndrome
- Interventions
- HZN-1116, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 16
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Napa, California + 13 more
- Conditions
- Evaporative Loss Dry Eye Disease
- Interventions
- Not listed
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Aqueous Deficient Dry Eye, Meibomium Gland Dysfunction
- Interventions
- Subjective Questionnaire, Measurement with wavefront sensor (right eye, then left eye), Instill Saline Drop
- Behavioral · Procedure · Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 20 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Dry Eye Syndromes, Keratoconjunctivitis Sicca
- Interventions
- rebamipide 2% ophthalmic suspension, placebo eye drops
- Drug
- Lead sponsor
- Kubota Vision Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 5
- States / cities
- Waterbury, Connecticut • Louisville, Kentucky • Lewiston, Maine + 2 more
- Conditions
- Dry Eye Disease
- Interventions
- OC-01 (varenicline 1.2mg/ml) nasal spray vs Placebo, Placebo (vehicle) nasal spray
- Drug · Other
- Lead sponsor
- Vance Thompson Vision - MT
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Bozeman, Montana
- Conditions
- Dry Eye Disease
- Interventions
- SI-614, Placebo
- Drug
- Lead sponsor
- Seikagaku Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 6
- States / cities
- Newport Beach, California • Louisville, Kentucky • Andover, Massachusetts + 3 more
- Conditions
- Dry Eye
- Interventions
- ECF843, ECF843 vehicle
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 718 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 52
- States / cities
- Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 46 more
- Conditions
- Dry Eye Syndromes, Dry Eye, Ocular Surface Disease
- Interventions
- Rinsada
- Device
- Lead sponsor
- Rinsada
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Sjogren's Syndrome, Interstitial Lung Disease, Primary Pulmonary Lymphoma (Disorder), Chronic Bronchiolitis, Bronchiectasis, Lung Diseases, Cystic Lung Disease, Lymphocytic Interst. Pneumonitis
- Interventions
- Not listed
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Dry Eye
- Interventions
- iTEAR100 treatment
- Device
- Lead sponsor
- Olympic Ophthalmics, Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 2
- States / cities
- Issaquah, Washington • Seattle, Washington
- Conditions
- Dry Eye, Kerato Conjunctivitis Sicca
- Interventions
- Tyrvaya Nasal Pump
- Drug
- Lead sponsor
- Oyster Point Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Dry Eye
- Interventions
- Lifitegrast 5% Ophthalmic Solution
- Drug
- Lead sponsor
- Bucci Laser Vision Institute
- Other
- Eligibility
- 60 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Wilkes-Barre, Pennsylvania
- Conditions
- Dry Eye Syndromes
- Interventions
- Intranasal Tear Neurostimulator (ITN) [TrueTear®]
- Device
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Keratoconjunctivitis Sicca
- Interventions
- Not listed
- Lead sponsor
- TearLab Corporation
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 314 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 6
- States / cities
- San Diego, California • Louisville, Kentucky • Chesterfield, Missouri + 3 more
- Conditions
- Keratoconjunctivitis Sicca
- Interventions
- Low Dose 0.155µg/mL SkQ1 ophthalmic solution, High Dose 1.55µg/mL SkQ1 ophthalmic solution, Placebo (Vehicle) opthalmic solution
- Drug
- Lead sponsor
- Mitotech, SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts